Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting
- PMID: 21572852
- PMCID: PMC3092323
Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting
Abstract
Background: Highly active antiretroviral therapy (HAART) has been associated with liver toxicity. The role of monitoring for liver toxicity has not been well studied in resource-limited settings (RLS).
Objectives: To determine the background prevalence and incidence of liver injury and describe the associated signs and symptoms of acute hepatitis after initiating HAART; and to determine the role of liver enzyme tests in monitoring hepatotoxicity.
Methods: In this prospective study, in Mulago Hospital AIDS Clinics, we consecutively enrolled adult patients initiated on one of three first line HAART regimens [Stavudine (d4T)-Lamivudine (3TC) and nevirapine (NVP); Zidovudine (AZT)-3TC and Efavirenz (EFV) or d4T-3TC-EFV]. We monitored ALT (alanine aminotransferase) and clinical evidence of acute hepatitis at baseline, 2(nd), 6(th), 10(th) and 14(th) week of therapy.
Results: Two hundred and forty HIV-positive HAART- naïve patients were enrolled in the study. The baseline prevalence of transaminitis was 1.7% with an incidence of 4.2% at 14 weeks. Grade 3-4 hepatotoxicity was documented in 1.3%. Jaundice was seen in grade 2-4 ALT elevations. Being on concurrent HAART and antituberculous drugs was associated with grade 2-4 toxicity compared to those who were only on HAART [OR; 16.0 (95% CI; 2.4-104.2)].
Conclusions: Incidence of severe hepatotoxicity within three months of first-line antiretroviral therapy was low, suggesting that routine measurement of transaminases may not be necessary in all patients initiating HAART in RLS. Routine measurement may be important in following patients on HAART and concurrent TB treatment as well as those with jaundice to avoid missing hepatotoxicity.
Keywords: HAART; Hepatotoxicity; Uganda.
Figures
Similar articles
-
Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.AIDS Patient Care STDS. 2008 Apr;22(4):337-44. doi: 10.1089/apc.2007.0093. AIDS Patient Care STDS. 2008. PMID: 18422462
-
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.J Infect Dis. 2002 Jul 1;186(1):23-31. doi: 10.1086/341084. Epub 2002 Jun 14. J Infect Dis. 2002. PMID: 12089658
-
Risk factors of severe hepatotoxicity among HIV-1 infected individuals initiated on highly active antiretroviral therapy in the Northwest Region of Cameroon.BMC Gastroenterol. 2022 Jun 3;22(1):286. doi: 10.1186/s12876-022-02305-x. BMC Gastroenterol. 2022. PMID: 35658835 Free PMC article.
-
Hepatotoxicity of antiretroviral therapy.AIDS Rev. 2003 Jan-Mar;5(1):36-43. AIDS Rev. 2003. PMID: 12875106 Review.
-
Deciphering the Molecular Mechanisms of HAART-Induced Hepatotoxicity.J Biochem Mol Toxicol. 2025 Feb;39(2):e70174. doi: 10.1002/jbt.70174. J Biochem Mol Toxicol. 2025. PMID: 39959953 Review.
Cited by
-
Acrolein enhances epigenetic modifications, FasL expression and hepatocyte toxicity induced by anti-HIV drug Zidovudine.Toxicol In Vitro. 2016 Sep;35:66-76. doi: 10.1016/j.tiv.2016.05.013. Epub 2016 May 26. Toxicol In Vitro. 2016. PMID: 27238871 Free PMC article.
-
Prevalence of hepatotoxicity among HIV-infected patients in Ethiopia: a systematic review and meta-analysis.BMC Infect Dis. 2022 Nov 9;22(1):826. doi: 10.1186/s12879-022-07838-w. BMC Infect Dis. 2022. PMID: 36352398 Free PMC article.
-
Clinicopathological correlates in HIV seropositive tuberculosis cases presenting with jaundice after initiating antiretroviral therapy with a structured review of the literature.BMC Infect Dis. 2012 Oct 14;12:257. doi: 10.1186/1471-2334-12-257. BMC Infect Dis. 2012. PMID: 23061403 Free PMC article. Review.
-
Hepatotoxicity and Liver-Related Mortality in Women of Childbearing Potential Living With Human Immunodeficiency Virus and High CD4 Cell Counts Initiating Efavirenz-Containing Regimens.Clin Infect Dis. 2021 Apr 26;72(8):1342-1349. doi: 10.1093/cid/ciaa244. Clin Infect Dis. 2021. PMID: 32161944 Free PMC article. Clinical Trial.
-
Liver Damage During Treatment with Reverse-Transcriptase Inhibitors in HIV Patients.Curr Health Sci J. 2024 Apr-Jun;50(2):181-197. doi: 10.12865/CHSJ.50.02.03. Epub 2024 Jun 30. Curr Health Sci J. 2024. PMID: 39371070 Free PMC article. Review.
References
-
- Laurent C, Diakhate N, Gueye NF, Toure MA, Sow PS, Faye MA, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. Aids. 2002;5; 16(10):1363–1370. - PubMed
-
- Weidle PJ, Mwebaze R, Sozi C, Rukundo G, Downing R, Hanson D, Ochola D, Mugyenyi P, Mermin J, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet Infect Dis. 2002;6(360(9326)):34–40. - PubMed
-
- Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;15;191(6):825–829. - PubMed
-
- Katabira ET, Kamya MR, editors. MOH. 2nd ed. Uganda: STD/AIDS Control Programme; 2008. National antiretroviral treatment and care guidelines for adults and children.
-
- Forna F LC, Solberg P, Asiimwe F, Were W, Mermin J, Behumbiize P, Tong T, et al. Clinical toxicity of highly active antiretroviral therapy in home-based-AIDS care program in rural Uganda. J acquir Imm Def Syndr. 2007;44:456–462. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical